Please provide your email address to receive an email when new articles are posted on . The Asthma Impairment and Risk Questionnaire (AIRQ) measures current control and future exacerbation risk. 35% ...

Mepolizumab significantly reduces exacerbations in patients with asthma and concurrent chronic obstructive pulmonary disease (COPD), with a 55% reduction in COPD exacerbations post initiation. A ...

In severe asthma, more exacerbations occur November through January, with respiratory infection as the most commonly identified trigger.

A single-inhaler triple therapy improved lung function in adults and adolescents with inadequately controlled asthma and was ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Improvement across all asthma control parameters was achieved after 12 months of biologic treatment, according to one study. Patients with severe asthma treated with either omalizumab, benralizumab, ...

The 2025 Lawrence and Nancy Golden Memorial Lectureship on Mind-Body Medicine focused on the psychobiology of asthma.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Wechsler: It's ...

The question of whether to alter beta-blocker therapy in patients with asthma has been reviewed extensively in the medical literature. [1,2,3,4,5] Cardioselective (beta-1) beta-blockers are ...

An anti-inflammation injectable drug can reduce mucus buildup and improve breathing among asthma patients, a new clinical ...